Early Detection, Lifetime Protection: Familial Hypercholesterolemia Genetic Testing
Care Process & Redesign
Yishun Health One Improvement Festival
National Healthcare Group
National University Health System
SingHealth
13 October 2025
The FHCARE study aims to reduce the risk of premature cardiovascular (CV) events within the Familial Hypercholesterolemia. The study will continually focus on improving long-term FH-management and health outcomes through FH-educational initiatives and.
Year Submitted: 2025
Published Date: 13 October 2025
Tags: Workflow Redesign, Quality Improvement, Care Process ＆ Redesign
About this Content
Aims
The FHCARE study aims to reduce the risk of premature cardiovascular (CV) events within the Familial Hypercholesterolemia (FH) population.
Background
FHCARE is a program established in 2015 to screen patients with very high cholesterol and family history of high cholesterol and premature cardiac diseases for FH. With the commencement of the Clinical Implementation Program (CIP) in 2023, a more organized FH research genetic test workflow for patients and cascade screening of family members was established.
Methods
The methodology includes establishing a standardized clinical workflow, partnering with CAP accredited labs, training study team members for genetic counselling, providing continuity of care post-genetic test, and engaging with various stakeholders and the public.
Results
Faster turnover time for genetic results, increased efficiency leading to more FH patient identification, increased training and understanding among healthcare professionals, and increased awareness through publicity and events.
Conclusion
The study will continually focus on improving long-term FH-management and health outcomes through FH-educational initiatives and constant streamlining of workflows when needed, achieving the goal of early detection and lifetime protection of FH patients.
Lessons Learnt
The importance of a centralized referral hub, standardized workflow, and adequate training to improve the efficiency of providing FH genetic testing to patients and their family members.
Additional Information
FHCARE works with doctors to identify and diagnose FH patients and assign them to care streams for timely and optimal treatment. The program also emphasizes the prevention of CVD in early stages, reducing future A&E admissions, and preventing double/unnecessary testing and appointments for FH patients.
Keywords
Genetic Testing, Familial Hypercholesterolemia, Cardiovascular
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | National Healthcare Group, National University Health System, SingHealth |
Organization(s) Involved | Khoo Teck Puat Hospital, Admiralty Medical Centre |
Platform(s) | Yishun Health One Improvement Festival |
Healthcare Professional Group(s) | Medical |
Applicable Specialty or Discipline | Cardiology, Clinical Research |
Project Lead(s) | Tavintharan S, Pek S.L.T |
Project Member(s) | Sanjaya Dissayanake |
Connect with this contributor!
KTPH & YCH Innovation & Improvement (I&I) Office - i-i@ktph.com.sg
Project Attachment
795_KTPH_OIF 2025_Early Detection, Lifetime Protection Familial Hypercholesterolemi.pdf